Multiple sclerosis

Accuracy of magnetic resonance imaging for the diagnosis of multiple sclerosis: systematic review.
[16565096] BMJ 332(7546): 875-84 (2006)

Diagnosis and treatment of multiple sclerosis.
[16513709] BMJ 332(7540): 525-7 (2006)

Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic review.
[12390057] Arch Intern Med 162(19): 2161-9 (2002)

Multiple sclerosis: what have we learned from magnetic resonance imaging studies?
[9521220] Arch Intern Med 158(6): 565-73 (1998)

Multiple sclerosis: treating symptoms, and other general medical issues.
[16478042] Cleve Clin J Med 73(2): 177-86 (2006)

Multiple sclerosis: advances in understanding, diagnosing, and treating the underlying disease.
[16444920] Cleve Clin J Med 73(1): 91-102 (2006)

The neuropsychiatry of multiple sclerosis.
[15101497] Can J Psychiatry 49(3): 157-63 (2004)

Psychiatric manifestations of multiple sclerosis: a review.
[8884033] Can J Psychiatry 41(7): 441-5 (1996)

Review of teriflunomide and its potential in the treatment of multiple sclerosis.
[19557143] Neuropsychiatr Dis Treat 5(-): 333-40 (2009)

Review of the clinical evidence for interferon beta 1a (Rebif) in the treatment of multiple sclerosis.
[18728744] Neuropsychiatr Dis Treat 4(2): 321-36 (2008)

Glatiramer acetate in the treatment of multiple sclerosis.
[19300558] Neuropsychiatr Dis Treat 3(2): 259-67 (2007)

The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration.
[17015227] Neuron 52(1): 61-76 (2006)

Diverse targets for intervention during inflammatory and neurodegenerative phases of multiple sclerosis.
[12797954] Neuron 38(5): 685-8 (2003)

The extracellular matrix in multiple sclerosis pathology.
[17854386] J Neurochem 103(4): 1293-301 (2007)

Multiple sclerosis: a battle between destruction and repair.
[17101032] J Neurochem 100(2): 295-306 (2007)

Neuropsychiatric manifestations of depression in multiple sclerosis: neuroinflammatory, neuroendocrine, and neurotrophic mechanisms in the pathogenesis of immune-mediated depression.
[17726912] Dialogues Clin Neurosci 9(2): 125-39 (2007)

Glatiramer acetate in multiple sclerosis: a review.
[17627671] CNS Drug Rev 13(2): 178-91 (2007)

Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases.
[17461891] CNS Drug Rev 13(1): 79-95 (2007)

Treatments for spasticity and pain in multiple sclerosis: a systematic review.
[14636486] Health Technol Assess 7(40): iii, ix-x, 1-111 (2003)

Epidemiologic evidence for multiple sclerosis as an infection.
[8269393] Clin Microbiol Rev 6(4): 382-427 (1993)

The cellular immunology of multiple sclerosis.
[10204572] J Leukoc Biol 65(4): 444-52 (1999)

The immunological basis for treatment of multiple sclerosis.
[17850581] Scand J Immunol 66(4): 374-82 (2007)

Complement in multiple sclerosis: its role in disease and potential as a biomarker.
[19040603] Clin Exp Immunol 155(2): 128-39 (2009)

Myelin repair: the role of stem and precursor cells in multiple sclerosis.
[17282989] Philos Trans R Soc Lond B Biol Sci 363(1489): 171-83 (2008)

Therapeutic strategies in multiple sclerosis. II. Long-term repair.
[10603622] Philos Trans R Soc Lond B Biol Sci 354(1390): 1711-20 (1999)

Therapeutic strategies in multiple sclerosis. I. Immunotherapy.
[10603621] Philos Trans R Soc Lond B Biol Sci 354(1390): 1697-710 (1999)

Nuclear magnetic resonance monitoring of treatment and prediction of outcome in multiple sclerosis.
[10603620] Philos Trans R Soc Lond B Biol Sci 354(1390): 1687-95 (1999)

Characterization of tissue damage in multiple sclerosis by nuclear magnetic resonance.
[10603619] Philos Trans R Soc Lond B Biol Sci 354(1390): 1675-86 (1999)

The pathophysiology of multiple sclerosis: the mechanisms underlying the production of symptoms and the natural history of the disease.
[10603618] Philos Trans R Soc Lond B Biol Sci 354(1390): 1649-73 (1999)

Axon damage and repair in multiple sclerosis.
[10603617] Philos Trans R Soc Lond B Biol Sci 354(1390): 1641-7 (1999)

The pathology of multiple sclerosis and its evolution.
[10603616] Philos Trans R Soc Lond B Biol Sci 354(1390): 1635-40 (1999)

The genetic epidemiology of multiple sclerosis.
[10603615] Philos Trans R Soc Lond B Biol Sci 354(1390): 1623-34 (1999)

Multiple sclerosis: the disease and its manifestations.
[10603614] Philos Trans R Soc Lond B Biol Sci 354(1390): 1615-22 (1999)

Tumor-like multiple sclerosis: report of four cases and literature review.
[17260503] Tumori 92(6): 559-62 (2006)

Insights into the molecular pathogenesis of progression in multiple sclerosis: potential implications for future therapies.
[16401734] Arch Neurol 63(1): 25-33 (2006)

Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations.
[16216934] Arch Neurol 62(10): 1519-30 (2005)

Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions.
[16157741] Arch Neurol 62(9): 1345-56 (2005)

Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement.
[15956157] Arch Neurol 62(6): 865-70 (2005)

Glatiramer acetate therapy: the plot thickens.
[15956155] Arch Neurol 62(6): 858-9 (2005)

Acinetobacter immune responses in multiple sclerosis: etiopathogenetic role and its possible use as a diagnostic marker.
[15642847] Arch Neurol 62(1): 33-6 (2005)

Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance.
[12135961] Brain 125(Pt 8): 1676-95 (2002)

The role of magnetic resonance techniques in understanding and managing multiple sclerosis.
[9549485] Brain 121 ( Pt 1)(-): 3-24 (1998)

Primary progressive multiple sclerosis.
[9217691] Brain 120 ( Pt 6)(-): 1085-96 (1997)

Multiple sclerosis: etiological mechanisms and future directions.
[14709772] Exp Biol Med (Maywood) 229(1): 12-20 (2004)

Developing therapeutics for the treatment of multiple sclerosis.
[16489371] NeuroRx 2(4): 638-49 (2005)

Imaging of multiple sclerosis: role in neurotherapeutics.
[15897951] NeuroRx 2(2): 277-303 (2005)

Multiple sclerosis: diagnosis and the management of acute relapses.
[15879043] Postgrad Med J 81(955): 302-8 (2005)

Multiple sclerosis: the impact of MR imaging.
[1546605] AJR Am J Roentgenol 158(4): 849-57 (1992)

Proton MR spectroscopy in multiple sclerosis: value in establishing diagnosis, monitoring progression, and evaluating therapy.
[1927795] AJR Am J Roentgenol 157(5): 1073-8 (1991)

Tissue-specific MR imaging in multiple sclerosis.
[19617445] AJNR Am J Neuroradiol 30(7): 1277-8 (2009)

Diffusion MR imaging in multiple sclerosis: technical aspects and challenges.
[17353305] AJNR Am J Neuroradiol 28(3): 411-20 (2007)

Multiple sclerosis: the role of MR imaging.
[16775258] AJNR Am J Neuroradiol 27(6): 1165-76 (2006)

Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines.
[16484429] AJNR Am J Neuroradiol 27(2): 455-61 (2006)

Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology.
[15760868] AJNR Am J Neuroradiol 26(3): 572-7 (2005)

Diffusion tensor MR imaging of gray matter in different multiple sclerosis phenotypes.
[12063212] AJNR Am J Neuroradiol 23(6): 899-900 (2002)

Perspectives on multiple sclerosis.
[9726464] AJNR Am J Neuroradiol 19(7): 1251-65 (1998)

Investigating multiple sclerosis with spectroscopic imaging: harbinger of a new paradigm.
[9672000] AJNR Am J Neuroradiol 19(6): 1002-3 (1998)

MR imaging of gray matter involvement in multiple sclerosis: implications for understanding disease pathophysiology and monitoring treatment efficacy.
[20044503] AJNR Am J Neuroradiol 31(7): 1171-7 (2010)

Dirty-appearing white matter: a disregarded entity in multiple sclerosis.
[19833799] AJNR Am J Neuroradiol 31(3): 390-1 (2010)

Cognitive deficits in multiple sclerosis: a systematic review.
[20730323] Arq Neuropsiquiatr 68(4): 632-41 (2010)

Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis.
[21895607] ASN Neuro 3(4): - (2011)

The role of natalizumab in the treatment of multiple sclerosis.
[20615052] Am J Manag Care 16(6 Suppl): S164-70 (2010)

Guidelines and best practices for appropriate use of dalfampridine in managed care populations.
[21761954] Am J Manag Care 17 Suppl 5 Improving(-): S154-60 (2011)

Is multiple sclerosis a mitochondrial disease?
[19607913] Biochim Biophys Acta 1802(1): 66-79 (2010)

Optic neuritis and risk of MS: differential diagnosis and management.
[19258465] Cleve Clin J Med 76(3): 181-90 (2009)

FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.
[19814729] Br J Pharmacol 158(5): 1173-82 (2009)

Astrocytes in multiple sclerosis: a product of their environment.
[18516496] Cell Mol Life Sci 65(17): 2702-20 (2008)

Value of oligoclonal band study in clinically isolated syndromes and multiple sclerosis.
[18759537] Expert Rev Neurother 8(9): 1279-80 (2008)

Epstein-Barr virus in the development of multiple sclerosis.
[18345964] Expert Rev Neurother 8(3): 331-3 (2008)

Autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis.
[17597968] Ann Acad Med Singapore 36(6): 421-6 (2007)

T cells in multiple sclerosis and experimental autoimmune encephalomyelitis.
[20682002] Clin Exp Immunol 162(1): 1-11 (2010)

The immune-modulatory role of apolipoprotein E with emphasis on multiple sclerosis and experimental autoimmune encephalomyelitis.
[20613949] Clin Dev Immunol 2010(-): 186813 (2010)

Genetics and pathogenesis of multiple sclerosis.
[19775910] Semin Immunol 21(6): 328-33 (2009)

The therapeutic potential of HDAC inhibitors in the treatment of multiple sclerosis.
[21373721] Mol Med 17(5-6): 442-7 (2011)

Development of oral immunomodulatory agents in the management of multiple sclerosis.
[21625416] Drug Des Devel Ther 5(-): 255-74 (2011)

New approaches in the management of multiple sclerosis.
[21151622] Drug Des Devel Ther 4(-): 343-66 (2010)

Acute disseminated encephalomyelitis and multiple sclerosis.
[20129937] Brain 133(Pt 2): 317-9 (2010)

Autoreactive CD8+ T cells in multiple sclerosis: a new target for therapy?
[15975943] Brain 128(Pt 8): 1747-63 (2005)

Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research.
[16632554] Brain 129(Pt 8): 1953-71 (2006)

Restoring the balance between disease and repair in multiple sclerosis: insights from mouse models.
[20647413] Dis Model Mech 3(9-10): 535-9 (2010)

Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis.
[21573085] Neuropsychiatr Dis Treat 7(-): 229-39 (2011)

Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis.
[21931494] Neuropsychiatr Dis Treat 7(-): 519-27 (2011)

3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of central nervous system diseases.
[20837848] Arch Neurol 67(9): 1062-7 (2010)

Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study.
[19433659] Arch Neurol 66(5): 593-9 (2009)

Emerging therapies for relapsing multiple sclerosis.
[19597083] Arch Neurol 66(7): 821-8 (2009)

Stimulation of transient receptor potential vanilloid 4 channel suppresses abnormal activation of microglia induced by lipopolysaccharide.
[22331560] Glia 60(5): 761-70 (2012)

Atacicept: targeting B cells in multiple sclerosis.
[21179612] Ther Adv Neurol Disord 3(4): 205-16 (2010)

Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice.
[21694816] Ther Adv Neurol Disord 4(3): 139-68 (2011)

The interferon beta therapies for treatment of relapsing-remitting multiple sclerosis: are they equally efficacious? A comparative review of open-label studies evaluating the efficacy, safety, or dosing of different interferon beta formulations alone or in combination.
[22010041] Ther Adv Neurol Disord 4(5): 281-96 (2011)

Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis.
[22010043] Ther Adv Neurol Disord 4(5): 319-32 (2011)

Practical considerations on the use of rituximab in autoimmune neurological disorders.
[21179602] Ther Adv Neurol Disord 3(2): 93-105 (2010)

Innovative monoclonal antibody therapies in multiple sclerosis.
[21180564] Ther Adv Neurol Disord 1(1): 43-52 (2008)

Escalating immunotherapy of multiple sclerosis.
[21180576] Ther Adv Neurol Disord 1(3): 181-92 (2008)

Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms.
[21180630] Ther Adv Neurol Disord 2(6): 50-61 (2009)

Long-term daclizumab therapy in relapsing-remitting multiple sclerosis.
[21180619] Ther Adv Neurol Disord 2(5): 291-7 (2009)

Monoclonal antibody therapy in multiple sclerosis: Paradigm shifts and emerging challenges.
[21124072] MAbs 2(6): 670-81 (2010)

Promising treatments of tomorrow for multiple sclerosis.
[20182576] Ann Indian Acad Neurol 12(4): 283-90 (2009)

Disease-modifying agents in multiple sclerosis.
[20182575] Ann Indian Acad Neurol 12(4): 273-82 (2009)

Management of acute exacerbations in multiple sclerosis.
[20182574] Ann Indian Acad Neurol 12(4): 264-72 (2009)

Examination of the role of magnetic resonance imaging in multiple sclerosis: A problem-orientated approach.
[20182573] Ann Indian Acad Neurol 12(4): 254-63 (2009)

Cerebrospinal fluid in multiple sclerosis.
[20182572] Ann Indian Acad Neurol 12(4): 246-53 (2009)

Neuromyelitis optica - an update: 2007-2009.
[20182570] Ann Indian Acad Neurol 12(4): 231-7 (2009)

The importance of NAD in multiple sclerosis.
[19149604] Curr Pharm Des 15(1): 64-99 (2009)

Emerging oral therapies for multiple sclerosis.
[17784852] Int J Clin Pract 61(11): 1922-30 (2007)

Interferons and natalizumab for multiple sclerosis.
[21289915] GMS Health Technol Assess 4(-): Doc09 (2008)

Diffusion imaging in multiple sclerosis: research and clinical implications.
[20882528] NMR Biomed 23(7): 865-72 (2010)

Varicella zoster virus and relapsing remitting multiple sclerosis.
[22096629] Mult Scler Int 2011(-): 214763 (2011)

Repeated intrathecal triamcinolone acetonide administration in progressive multiple sclerosis: a review.
[22096630] Mult Scler Int 2011(-): 219049 (2011)

Potential impact of B cells on T cell function in multiple sclerosis.
[22096636] Mult Scler Int 2011(-): 423971 (2011)

When to initiate disease-modifying drugs for relapsing remitting multiple sclerosis in adults?
[22096641] Mult Scler Int 2011(-): 724871 (2011)

Review: Mitochondria and disease progression in multiple sclerosis.
[19076696] Neuropathol Appl Neurobiol 34(6): 577-89 (2008)

Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.
[20061941] Clin Neuropharmacol 33(2): 91-101 (2010)

Seizures in patients with multiple sclerosis: epidemiology, pathophysiology and management.
[19739692] CNS Drugs 23(10): 805-15 (2009)

Evaluating epigenetic landmarks in the brain of multiple sclerosis patients: a contribution to the current debate on disease pathogenesis.
[18930111] Prog Neurobiol 86(4): 368-78 (2008)

Multiple sclerosis, cannabinoids, and cognition.
[18305283] J Neuropsychiatry Clin Neurosci 20(1): 36-51 (2008)

Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
[20439849] Neurology 74(18): 1463-70 (2010)

Cyclophosphamide therapy in pediatric multiple sclerosis.
[19439723] Neurology 72(24): 2076-82 (2009)

Psychiatric issues in multiple sclerosis.
[17938046] Psychiatr Clin North Am 30(4): 803-17 (2007)

Clinical implications of a possible role of vitamin D in multiple sclerosis.
[19399382] J Neurol 256(9): 1468-79 (2009)

Manipulating antigenic ligand strength to selectively target myelin-reactive CD4+ T cells in EAE.
[19904613] J Neuroimmune Pharmacol 5(2): 176-88 (2010)

Current views on the roles of Th1 and Th17 cells in experimental autoimmune encephalomyelitis.
[20107924] J Neuroimmune Pharmacol 5(2): 189-97 (2010)

Studies in the modulation of experimental autoimmune encephalomyelitis.
[20401539] J Neuroimmune Pharmacol 5(2): 168-75 (2010)

Modulation of cannabinoid receptor activation as a neuroprotective strategy for EAE and stroke.
[19255856] J Neuroimmune Pharmacol 4(2): 249-59 (2009)

Role of the innate immune system in the pathogenesis of multiple sclerosis.
[19931190] J Neuroimmunol 221(1-2): 7-14 (2010)

Control of experimental autoimmune encephalomyelitis by CD4+ suppressor T cells: peripheral versus in situ immunoregulation.
[17900707] J Neuroimmunol 191(1-2): 61-9 (2007)

The dynamics of effector T cells and Foxp3+ regulatory T cells in the promotion and regulation of autoimmune encephalomyelitis.
[17916388] J Neuroimmunol 191(1-2): 51-60 (2007)

Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple sclerosis.
[17196667] J Neuroimmunol 184(1-2): 37-44 (2007)

Neuroprotective effects of the complement terminal pathway during demyelination: implications for oligodendrocyte survival.
[19577811] J Neuroimmunol 213(1-2): 3-11 (2009)

The role of citrullinated proteins suggests a novel mechanism in the pathogenesis of multiple sclerosis.
[17031564] Neurochem Res 32(2): 251-6 (2007)

Proton magnetic resonance spectroscopy in multiple sclerosis.
[19064199] Neuroimaging Clin N Am 19(1): 45-58 (2009)

Th17 cells in autoimmune demyelinating disease.
[20195867] Semin Immunopathol 32(1): 71-7 (2010)

Regulatory CD4+CD25high T cells, activated CD4+CD25highCD127high T cells and multiple sclerosis.
[20477058] Expert Rev Clin Immunol 5(2): 115-7 (2009)

Parasite immunomodulation in autoimmune disease: focus on multiple sclerosis.
[20477636] Expert Rev Clin Immunol 5(5): 487-9 (2009)

Autoantibodies and neurodegeneration in multiple sclerosis.
[18521063] Lab Invest 88(8): 796-807 (2008)

The role of dendritic cells in CNS autoimmunity.
[20217033] J Mol Med (Berl) 88(6): 535-44 (2010)

The contribution of gammadelta T cells to the pathogenesis of EAE and MS.
[19199938] Curr Mol Med 9(1): 15-22 (2009)

Multiple sclerosis and regulatory T cells.
[18763026] J Clin Immunol 28(6): 697-706 (2008)

Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis.
[19707422] Biologics 3(-): 369-76 (2009)

Hematopoietic SCT for the treatment of multiple sclerosis.
[20697363] Bone Marrow Transplant 45(12): 1671-81 (2010)

A case for regulatory B cells in controlling the severity of autoimmune-mediated inflammation in experimental autoimmune encephalomyelitis and multiple sclerosis.
[21145597] J Neuroimmunol 230(1-2): 1-9 (2011)

miRNAs in multiple sclerosis: regulating the regulators.
[20888650] J Neuroimmunol 229(1-2): 3-4 (2010)

Natalizumab for relapsing-remitting multiple sclerosis.
[21193250] Neurologia 26(6): 357-68 (2011)

Optical coherence tomography (OCT) in optic neuritis and multiple sclerosis.
[20605617] Rev Neurol (Paris) 166(12): 978-86 (2010)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Fatal error: Uncaught Error: Call to undefined function mysql_connect() in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Multiple sclerosis.php:92 Stack trace: #0 {main} thrown in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Multiple sclerosis.php on line 92